Immobilized CD24 hFc Chimera, Human , hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-CD24 Antibody, hFc Tag with the EC50 of 0.58 μg/ml determined by ELISA.

The purity of CD24 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

CD24 hFc Chimera, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.

CD24 hFc Chimera, Human

CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.

产品编号	Z04175
规格	100 μg 500 μg 大单询价
数量
价格	￥3500


联系我们

产品简介

Species

Human

Protein Construction

CD24 (Ser27-Gly59) Accession # P25063	hFc
N-term	C-term

Purity

> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC

Endotoxin Level

Less than 1EU per μg by the LAL method.

Biological Activity

Measured by its binding ability in a functional ELISA. Immobilized CD24 hFc Chimera, Human at 0.5μg/ml (100μl/well) on the plate can bind Biotinylated Anti-CD24 Antibody, hFc Tag. Test result was comparable to standard batch.

Expression System

HEK293

Theoretical Molecular Weight

29.9 kDa

Apparent Molecular Weight

Due to glycosylation, the protein migrates to 45-55 kDa based on Bis-Tris PAGE result.

Formulation

Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4).

Reconstitution

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Storage & Stability

Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

图例

The purity of CD24 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

CD24 hFc Chimera, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.

技术背景

Target Background	CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.
Synonyms	CD 24; CD24 molecule; CD24A; FLJ22950; FLJ43543; MGC75043

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.